In rheumatoid arthritis (RA), biologic DMARDs (bDMARDs), especially TNF inhibitors, decrease the risk of hospitalization, while rituximab and systemic corticosteroids increase the hospitalization risk; thus, the risk of severe COVID-19 infection also depends largely on treatment modalities. This evidence concerns the gene TNF and rheumatoid arthritis.